Navigation Links
Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode
Date:10/26/2011

eatments. We also use TomoDirect for conventional breast treatments when it offers a dosimetric advantage over Helical TomoTherapy."

Accuray's TomoHD Treatment System is a comprehensive solution that efficiently handles clinical indications of any complexity. The system offers both TomoDirect and TomoHelical treatment modes to allow clinicians to deliver treatment options for a range of clinical indications and enables daily 3D CT imaging of every patient, prior to each treatment, to maximize treatment accuracy. The TomoDirect modality is efficient in applying multiple targeted radiation beams to the tumor for more routine cases while TomoHelical is designed for more complex cases, delivering radiation throughout multiple 360 degree gantry rotations.

"The combination of TomoDirect and TomoHelical on the TomoHD System creates a single efficient and clinically flexible radiation therapy treatment solution," said Omar Dawood M.D., M.P.H., senior vice president, Global Medical Affairs, Accuray Incorporated. "By expanding the reach of TomoTherapy technology, the addition of TomoDirect allows physicians to offer the highest quality treatments tailored for each individual patient's specific clinical needs. The increase in global adoption of TomoDirect is a testament to the clinical benefits of the technology."

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Accuray Incorporated to Speak at 2011 Wedbush Life Sciences: Management Access Conference
2. SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy
3. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2011
4. Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets Healthcare Conference
5. Accuray Incorporated to Speak at Wells Fargo Securities Healthcare Conference
6. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO
7. Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference
8. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
9. 10 Percent of U.S. Installed Base Signs on to Use Accuray Treatment Planning Service
10. Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results
11. Accuray Incorporateds CEO to Speak at 27th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
(Date:7/29/2014)... CLARA, Calif. , July 29, 2014 /PRNewswire-iReach/ ... services agreement with FORMA Therapeutics, Inc., to provide ... and proprietary fragment-based lead discovery platform for novel ... really excited about the opportunity to work with ... fields of epigenetics and protein homeostasis. FORMA Therapeutics, ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in automated ... for hospitals, will be exhibiting at booth #209 at ... & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... hospitals cleaner, reducing infection risk and saving millions in ... Staff will be available at booth #209 to ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... TUSTIN, Calif., Sept. 1 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 ... New York Palace Hotel in New York City. , , ... the Investors section of Peregrine,s website at www.peregrineinc.com . ...
... COPENHAGEN and OSLO, September ... medicines company, today announced that it,has appointed two ... Robert Burns, previously CEO of Celldex Therapeutics Inc., ... new Chief Executive,Officer. Dr Alexander Duncan, previously SVP ...
... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that its Senior ... will present a corporate overview at the upcoming Rodman ... September 9, 2009 at 12:30 p.m. (eastern time) in ...
Cached Biology Technology:Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development 3
(Date:7/29/2014)... If you,ve ever ordered the wrong food at a restaurant, ... may have less to do with what you want and ... After analyzing 217 menus and the selections of over 300 ... International Journal of Hospitality Management showed that when it ... most: what you see on the menu and how you ...
(Date:7/29/2014)... recover from the debilitating effects of a stroke ... knowledge of neurophysiology as well as effective therapy. ... outcomes has been the primary focus of research ... since he joined the NJIT faculty more than ... is underscored by substantial funding from sources such ...
(Date:7/29/2014)... have developed an easier method to create DNAprotein ... involved in diagnosing diseases. , DNA linked to ... partnership that can be used in diagnostic techniques, ... tag proteins with DNA can be used ... visualisation of biological material. The method also provides ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... in their response to sleep deprivation, but the biological ... Researchers have now found that a genetic difference in ... sensitive to the effects of sleep deprivation. The findings, ... the University of Surrey's Sleep Research Center, appear online ...
... upon a massive database established with funds from the ... of the National Institutes of Health (NIH), scientists have ... influenza A virus epitopes--the critical sites on the virus ... reported by researchers at the La Jolla Institute for ...
... first draft of the horse genome sequence has been ... use by biomedical and veterinary researchers around the globe, ... today. , The $15 million effort to sequence the ... of the horse (Equus caballus) was funded by the ...
Cached Biology News:Individual differences in a clock gene predict decline of performance during sleep deprivation 2New details on how the immune system recognizes influenza 2New details on how the immune system recognizes influenza 3New details on how the immune system recognizes influenza 4Horse genome assembled 2Horse genome assembled 3
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Biology Products: